Clinical Trial Update: Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/2 trial evaluating ZVS203e for retinitis pigmentosa caused by RHO gene mutations; recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• ZVS203e

Snippet

Sponsor: Chigenovo Co., Ltd | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING